For Alzheimer Agitation, a Novel, Oral NMDA Inhibitor Could be the Next Targeted Treatment
Geriatric psychiatrist and neurocognitive researcher George Grossberg, MD, highlights the mechanism of action for the new dextromethorphan/bupropion combination.
Expert Perspectives 2024: Treatment for Agitation in Alzheimer Disease with George Grossberg, MD
Agitation affects at least one half of adults with Alzheimer disease; geriatric psychiatrist Grossberg explains the symptoms and new treatments in this year's video series.
Pearls for Primary Care: How to Talk About Agitation in Alzheimer Disease with Caregivers
A geriatric psychiatrist talks about the importance of asking caregivers about behavior in order to understand and treat agitation in Alzheimer dementia.
